Hua Medicine of Shanghai expects to spend $200 million over the next three years on its novel oral diabetes 2 treatment, dorzagliatin (see story). The company will raise additional capital for the effort and then IPO, possibly in Hong Kong or the US. The funds will underwrite Phase III development of its GKA product and commercialization. Ultimately, Hua hopes dorzagliatin will generate annual revenues of $3 billion, a 15% slice of the China type 2 diabetes market, once the drug is approved. Hua expects China approval in 2020.

Suzhou Kintor Pharma raised $44 million in a funding led by Shenzhen Green Pine Capital Partners (see story). Established in 2009, Kintor is an innovative high-tech pharma developing novel products. Since its founding, the company has received over 25 Significant New Drug Creation awards, plus the China Science and Technology Ministry's small and mid-size enterprise innovation funding support along with other awards.  

Lepu Medical Technology (Beijing) (SHZ: 300003) acquired a 13% stake in Australia's Viralytics (ASX: VLA, OTC: VRACY) via a $23.3 million private placement of Viralytics' shares (see story). Viralytics will use the funds for an Australian Phase III trial of CAVATAK, its oncolytic immunotherapy based on a common cold virus. Lepu has started Chinaclinical trials of its own PD-1 and PD-L1 checkpoint inhibitors, a class of drugs that are expected to be effective adjuncts to CAVATAK. Besides pharmaceutical drugs, Lepu is involved in medical devices, healthcare services, and private hospitals.  

Fosun Pharma (SHA: 600196; HK: 2196) acquired China rights to market a novel treatment for Parkinson's disease from Portugal's BIAL in an $18 million agreement (see story). BIAL developed Ongentys® (opicapone) as a once-daily adjunctive therapy to levodopa/DOPA decarboxylase inhibitors. It was approved in the EU in 2016. Wanbang Biopharma, a Fosun Pharma subsidiary, will commercialize the drug in China, paying $3 million upfront and up to $15 million in milestones.